In the first half of the year, Kasai Bio’s sales of long-chain dibasic acids increased slightly, and the application and development of a series of bio-based polyamides and composite materials in various fields continued.

In the first half of the year, the company’s production bases and construction projects continued to advance. The company’s project construction in Shanxi Synthetic Bio Industry Ecological Park has been delayed. The bio-process sebacic acid project with an annual output of 40,000 tons is expected to be put into trial production in the third quarter of 2022; The 10,000-ton bio-based polyamide project is under construction.

According to the semi-annual report, the company’s three production plants – Kasai Jinxiang, Wusu Technology, and Wusu Materials have obtained two silver and one bronze certification rating from EcoVadis, an international authoritative corporate social responsibility (CSR) evaluation agency.

In the first half of the year, Kasai Bio continued to strengthen R&D investment, which increased from 56.5187 million yuan last year to 86.4966 million yuan this year, a year-on-year increase of 53.04%; the number of R&D personnel increased from 229 in the same period last year to 389 this year, an increase of 69.87%.

From the perspective of research projects, the company’s key research and development projects are in steady progress, and the application development of a series of bio-based polyamides and composite materials in various fields is also in progress. Among them, the application of bio-based polyamide composite materials is expected to enter the large-scale application stage of “replacing steel with plastic and plastic with plastic” for replacing metal and thermosetting materials; the high-value utilization project of agricultural waste is also in Continue to optimize.

In addition, the company is also continuing to work on the layout of the patent pool to consolidate its own moat of technological innovation. In the first half of 2022, 46 new patents were granted, and a total of 288 patents were obtained. At the same time, the company’s intellectual property rights protection work has achieved phased results and has been recognized by professional competent authorities. The two winning cases, “V. Hanlin for Infringement of Invention Patent Right” and “Hanlin v. Kasai for Invalidation of Invention Patent Invalidation Administrative Dispute”, were selected as 50 typical intellectual property cases of the Supreme Court. Among them, “v. Hanlin for infringement of invention patent rights” was also selected as one of the top ten typical cases of intellectual property protection in Qingdao in 2021.